UFPT:NSC-UFP Technologies Inc. (USD)

EQUITY | Medical Devices | NASDAQ Capital Market

Last Closing

USD 211.92

Change

+18.71 (+9.68)%

Market Cap

USD 0.18B

Volume

0.20M

Analyst Target

USD 50.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

UFP Technologies Inc is a designer and custom converter of foams, plastics, composites and natural fiber materials, providing solutions to customers mainly within the medical, automotive, aerospace & defense, & packaging markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-09 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.16 (-0.23%)

USD 23.46B
PODD Insulet Corporation

-3.93 (-1.57%)

USD 17.22B
MASI Masimo Corporation

+0.47 (+0.31%)

USD 7.80B
BRKR Bruker Corporation

-1.46 (-3.87%)

USD 5.53B
IRTC iRhythm Technologies Inc

+1.01 (+1.01%)

USD 3.28B
PRCT Procept Biorobotics Corp

+0.22 (+0.42%)

USD 2.85B
TMDX TransMedics Group Inc

+2.86 (+3.35%)

USD 2.73B
QDEL Quidel Corporation

-0.10 (-0.40%)

USD 2.42B
LIVN LivaNova PLC

+0.51 (+1.45%)

USD 1.95B
NVCR Novocure Ltd

-0.25 (-1.58%)

USD 1.81B

ETFs Containing UFPT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.33% 66% D+ 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.33% 66% D+ 46% F
Trailing 12 Months  
Capital Gain -10.56% 71% C- 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.56% 71% C- 47% F
Trailing 5 Years  
Capital Gain 420.82% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 420.82% 100% F 95% A
Average Annual (5 Year Horizon)  
Capital Gain 59.31% 85% B 90% A-
Dividend Return 59.31% 85% B 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.34% 82% B 60% D-
Risk Adjusted Return 195.49% 100% F 100% F
Market Capitalization 0.18B 91% A- 78% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.10 44% 33%
Price/Book Ratio 4.72 32% 24%
Price / Cash Flow Ratio 24.30 13% 12%
Price/Free Cash Flow Ratio 18.89 12% 18%
Management Effectiveness  
Return on Equity 18.76% 95% 89%
Return on Invested Capital 15.73% 84% 82%
Return on Assets 10.22% 99% 95%
Debt to Equity Ratio 51.60% 51% 39%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.